Start free

SOPHiA Genetics SA (SOPH) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 17, 2026.

Filings shown
82
Open-market buys
3
Open-market sells
91
Buys, 10b5-1 box not checked
3 of 3

Counts cover the 82 most recent Form 4 filings Tradune holds for SOPH (filed May 12 – Nov 17, 2026); the score below covers only the trailing 90 days (2 buys, 30 sells). SEC EDGAR Form 4 filings for SOPH last checked Nov 21, 2026, 09:00 UTC; the latest SOPH filing Tradune holds was filed Nov 17, 2026. This is not guaranteed to be the complete record — see SOPH's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 31 filings Tradune holds for SOPH filed Aug 26 – Nov 17, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

31 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
28 sales· 183,331 sh
checkbox disclosed
On filings with the box not checked
3 sales· 5,216 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Zhenyu XuChief Scientific Officer 0 5 — 29,394 −$241,257
Philippe MenuChief Medical Officer 0 5 — 27,394 −$217,615
Jurgi CamblongExecutive Chairman 0 4 — 65,672 −$519,265
Daan Van WellChief Legal Officer 0 4 — 14,971 −$117,142
Ross MukenChief Executive Officer 1 2 20,000 10,260 +$137,188 / −$83,486
George CardozaChief Financial Officer 1 2 20,000 2,366 +$141,200 / −$19,345
Kathy L. HibbsDirector 0 3 — 18,750 −$153,528
Abhimanyu VermaChief Technology Officer 0 3 — 15,284 −$127,929
Kevin PuylaertChief Sales Officer 0 2 — 216 −$1,737
Manuela ValenteChief People Officer 0 1 — 4,240 −$34,487

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

61/ 100

Purchase cluster
2 distinct buyers2 buy · 30 sell txofficer buying

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

Weekly signal history

SOPH appeared in 1 archived weekly edition as a multi-insider cluster, a top net buyer, or both. These are frozen weekly snapshots, not a complete filing history.

  1. Week of Nov 10, 2026
    2 insiders buying · $278,388 net

An entry means this company met that edition’s displayed cluster or top-buyer threshold. Missing weeks do not mean no insider transaction occurred. All figures are derived from SEC Form 4 filings; open-market buys minus sales are shown as net only when every transaction value was disclosed.

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at SOPH

Insiders reported 3 open-market purchases of SOPH between May 12, 2026 and Nov 17, 2026, across 2 distinct buyers. The most recent purchase was reported by Ross Muken (Chief Executive Officer) on Nov 6, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Daan Van Well Chief Legal Officer · filed Nov 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 1,224 $7.73 330,081 −0.4% Nov 16, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Zhenyu Xu Chief Scientific Officer · filed Nov 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 4,000 $7.96 537,493 −0.7% Nov 13, 2026
Philippe Menu Chief Medical Officer · filed Nov 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 5,000 $7.68 190,993 −2.6% Nov 12, 2026
Kathy L. Hibbs Director · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 6,250 $7.76 90,742 −6.4% Nov 10, 2026
Jurgi Camblong Executive Chairman · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 8,500 $7.76 3,378,650 −0.3% Nov 10, 2026
Daan Van Well Chief Legal Officer · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 1,411 $7.44 331,305 −0.4% Nov 9, 2026
George Cardoza Chief Financial Officer · filed Nov 9, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 20,000 $7.06 326,726 +6.5% Nov 6, 2026
Ross Muken Chief Executive Officer · filed Nov 9, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 20,000 $6.86 680,391 +3.0% Nov 6, 2026
Zhenyu Xu Chief Scientific Officer · filed Oct 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 4,000 $7.18 541,493 −0.7% Oct 13, 2026
Philippe Menu Chief Medical Officer · filed Oct 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 5,000 $7.26 195,993 −2.5% Oct 12, 2026
Jurgi Camblong Executive Chairman · filed Oct 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 8,500 $7.26 3,387,150 −0.3% Oct 12, 2026
Daan Van Well Chief Legal Officer · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 6,168 $8.12 332,716 −1.8% Oct 5, 2026
Manuela Valente Chief People Officer · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 4,240 $8.13 206,210 −2.0% Oct 5, 2026
Abhimanyu Verma Chief Technology Officer · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 5,284 $8.12 166,887 −3.1% Oct 5, 2026
Kevin Puylaert Chief Sales Officer · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 185 $8.06 147,763 −0.1% Oct 5, 2026
Open-market sale 10b5-1 box not checked 31 $7.92 147,732 −0.0% Oct 5, 2026
George Cardoza Chief Financial Officer · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 1,592 $8.10 306,726 −0.5% Oct 5, 2026
Philippe Menu Chief Medical Officer · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 7,394 $8.13 200,993 −3.5% Oct 5, 2026
Jurgi Camblong Executive Chairman · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 40,172 $8.13 3,395,650 −1.2% Oct 5, 2026
Zhenyu Xu Chief Scientific Officer · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 7,394 $8.12 545,493 −1.3% Oct 5, 2026
Ross Muken Chief Executive Officer · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 9,838 $8.13 660,391 −1.5% Oct 5, 2026
George Cardoza Chief Financial Officer · filed Sep 22, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 774 $8.33 308,318 −0.3% Sep 21, 2026
Ross Muken Chief Executive Officer · filed Sep 22, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 422 $8.33 670,229 −0.1% Sep 21, 2026
Philippe Menu Chief Medical Officer · filed Sep 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 5,000 $7.88 208,387 −2.3% Sep 14, 2026
Zhenyu Xu Chief Scientific Officer · filed Sep 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 4,000 $7.88 552,887 −0.7% Sep 14, 2026
Daan Van Well Chief Legal Officer · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 6,168 $7.63 338,884 −1.8% Sep 11, 2026

Listing the 25 most recent of 82 Form 4 filings held for SOPH; the 57 older filings (filed May 12 – Sep 14, 2026) are counted above but not listed here — see SOPH's full Form 4 filing history on SEC EDGAR.

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to SOPH's (Nov 17, 2026).

Frequently asked about SOPH insider activity

How many insiders bought SOPH stock in these Form 4 filings?

2 distinct insiders at SOPHiA Genetics SA reported 3 open-market purchases (Form 4 code P) of SOPH shares between May 12, 2026 and Nov 17, 2026, the most recent filed by Ross Muken (Chief Executive Officer) on Nov 6, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for SOPH?

The most recent Form 4 on this page was filed by Daan Van Well (Chief Legal Officer) on Nov 17, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market SOPH insider sale shown?

The largest open-market sale among the filings shown was 40,172 SOPH shares at $8.13 (about $326,526) by Jurgi Camblong (Executive Chairman) on Oct 5, 2026. Value is shares × the price reported on the Form 4; that Form 4 has the Rule 10b5-1 box checked.

Do the recent SOPH insider purchases have the Form 4 10b5-1 box checked?

No. All 3 SOPH open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Ross Muken (Chief Executive Officer) on Nov 6, 2026, 20,000 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for SOPH — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.